TRB

TRB Chemedica is a Swiss-based pharmaceutical company that focuses on the development and commercialization of products in rheumatology, ophthalmology, and neurology. Established in 1980, the company has built a significant presence in the global market through its expertise in hyaluronic acid and diacerein research. Its product portfolio includes well-known brands such as Ostenil for the treatment of osteoarthritis and Vismed for managing dry eye syndrome. TRB Chemedica maintains a vertically integrated structure with its own research, development, and manufacturing facilities located in Switzerland. The company operates through a network of subsidiaries and distributors across more than 60 countries. It is recognized for its commitment to high-quality manufacturing standards and evidence-based clinical solutions.